Hao Miao, Xu Haiming, Li Min, Jiao Dan
Scientific Research Center, China-Japan Union Hospital of Jilin University, Changchun, China.
Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun, China.
Front Pharmacol. 2025 Aug 7;16:1634703. doi: 10.3389/fphar.2025.1634703. eCollection 2025.
Colorectal cancer (CRC) is the third most common malignant tumor globally, and its development is closely related to interactions between the host and microbes. Recent studies have shown that the diversity of intratumoral microbiota significantly influences CRC progression and responses to immune therapy. This influence occurs through mechanisms such as immune microenvironment regulation, metabolic reprogramming, and epigenetic modifications. However, there is still a lack of systematic analysis regarding the diversity of intratumoral microbiota in CRC and its immune regulatory mechanisms, particularly in the metabolic and immune regulation. This article presents a systematic review of the compositional characteristics of intratumoral microbiota in CRC, the associated immune regulatory mechanisms, and their roles in chemotherapy and immunotherapy. It also discusses challenges like standardizing microbiome detection methods and the ethics of clinical translation, while proposing a strategy for integrating multi-omics using artificial intelligence. This article provides a theoretical basis for developing personalized treatment regimens that target the microbiota.
结直肠癌(CRC)是全球第三大常见恶性肿瘤,其发展与宿主和微生物之间的相互作用密切相关。最近的研究表明,肿瘤内微生物群的多样性显著影响结直肠癌的进展以及对免疫治疗的反应。这种影响通过免疫微环境调节、代谢重编程和表观遗传修饰等机制发生。然而,关于结直肠癌肿瘤内微生物群的多样性及其免疫调节机制,特别是在代谢和免疫调节方面,仍然缺乏系统的分析。本文对结直肠癌肿瘤内微生物群的组成特征、相关免疫调节机制及其在化疗和免疫治疗中的作用进行了系统综述。它还讨论了微生物组检测方法标准化和临床转化伦理等挑战,同时提出了一种使用人工智能整合多组学的策略。本文为制定针对微生物群的个性化治疗方案提供了理论依据。
Front Pharmacol. 2025-8-7
Arch Ital Urol Androl. 2025-6-30
Cochrane Database Syst Rev. 2018-2-6
Probiotics Antimicrob Proteins. 2025-2-26
Int J Biol Macromol. 2025-4
Front Immunol. 2024-11-29
Int J Food Microbiol. 2025-1-30